Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 28, 2015 8:44 PM ET

Biotechnology

Company Overview of Blueprint Medicines Corp.

Company Overview

Blueprint Medicines Corp., an oncology company, engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. The company develops a platform that combines genomics with a novel library of kinase inhibitors to enable the development of highly selective compounds against clear genomic driver targets. Its products include KIT D816V, a validated driver mutation in aggressive systemic mastocytosis; isoform selective inhibitors of FGFR4; and programs against known and novel kinase fusions and resistance mutants. Blueprint Medicines Corp. has a strategic collaboration with Alexion. The company was incorporated in 2008 and is based in Cambrid...

215 First Street

Cambridge, MA 02142

United States

Founded in 2008

59 Employees

Phone:

617-374-7580

Key Executives for Blueprint Medicines Corp.

Chief Executive Officer
Age: 43
Executive Chairman
Age: 56
Co-Founder and Director
Age: 42
Chief Business Officer
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2014.

Blueprint Medicines Corp. Key Developments

Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease

Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. Blueprint Medicines will apply its kinase-focused drug discovery platform to identify and optimize drug candidates and will conduct all research activities prior to the filing of an Investigational New Drug (IND) application with the Food and Drug Administration. Alexion will be responsible for the development and commercialization of these Blueprint Medicines' drug candidates under the collaboration. Under the terms of the agreement, Blueprint Medicines will receive an upfront payment of $15 million and will be reimbursed for all research expenses. Blueprint Medicines is eligible to receive over $250 million in payments upon the successful achievement of pre-specified preclinical, clinical, regulatory and commercial milestones. In addition, Blueprint Medicines will be eligible to receive royalty payments following the commercialization of the product.

Blueprint Medicines Appoints Anthony (Andy) Boral as Senior Vice President, Clinical Development

Blueprint Medicines announced the appointment of Anthony (Andy) Boral, M.D., Ph.D., as Senior Vice President, Clinical Development. Dr. Boral joins Blueprint Medicines from Novartis Institutes for BioMedical Research, where he served for four years as Executive Director, Oncology Clinical Research. At Blueprint Medicines, he will join the executive management team and be responsible for clinical research and operations as well as regulatory affairs. Dr. Boral brings more than 15 years of leadership in drug development. He also spent two years on staff in the Thoracic Oncology group at Massachusetts General Hospital.

Blueprint Medicines Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM

Blueprint Medicines Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jeffrey W. Albers, Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
Lexigen Pharmaceuticals Corp. United States
Surgical Technologies, Inc. United States
Araxes Pharma, LLC United States
Topical Analgesic Concepts, LLC United States
Effective Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 10, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Blueprint Medicines Corp., please visit www.blueprintmedicines.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.